Review ArticleLiquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Keywords
Cited by (0)
Drs. Rolfo and Mack contributed equally to this paper.
Disclosure: Dr. Rolfo has received nonfinancial research support from OncoDNA and other support from Guardant Health. Dr. Mack has received personal fees from Guardant Health and Astra Zeneca. Dr. Scagliotti has received personal fees from Lilly, Roche, Pfizer, Astra Zeneca, Clovis, and Merck Sharp & Dohme. Dr. Barlesi has received personal fees from Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd., Novartis, Merck, Merck Sharp & Dohme, Pierre Fabre, Pfizer, and Takeda. Dr. Mok has received a grant from XCovery; has received grants and personal fees from Astra Zeneca, Roche/Genentech, Bristol-Myers Squibb, Boehringer Ingelheim, Novartis, Merck Sharp & Dohme, Pfizer, Clovis Oncology, SFJ Pharmaceuticals, Taiho, Eisai, and Takeda; personal fees from Eli Lilly, Merck Serono, Vertex, ACEA Biosciences, Oncogenex, Celgene, Ignyta Inc., Fishawack Facilitate Ltd., Janssen, and ChiMed; and has a nonfinancial relationship with geneDecode. Dr. Peled has received grants and personal fees from Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, NovellusDx, FMI, and Gaurdant360. Dr. Pirker has received personal fees from Astra Zeneca, Boehringer Ingelheim, Merck Sharp & Dohme, and Genmab Roche. Dr Raez has received grants from NantOmics, Exosomes DX, Liquid Genomics, and Biocept. Dr. Reck has received personal fees from Hoffmann-La Roche, Lilly, Bristol-Myers Squibb, Merck Sharp & Dohme, Merck, Astra Zeneca, Boehringer Ingelheim, Celgene, and Pfizer. Dr. Riess has received personal fees from Takeda, Celgene, Clovis, AbbVie, and Medtronic; and has received grants from Merck, Astra Zeneca, Novartis, and Millenium. Dr. Sequist has received personal fees from Bristol-Myers Squibb, Astra Zeneca, Pfizer, and Genentech; and has been an unpaid consultant for Boehringer Ingelheim, Merrimack, Novartis, and Clovis Oncology. Dr. Sholl has received personal fees from GfK and Genentech. Dr. Tan has received grants from Novartis, Bayer, Astra Zeneca, and GlaxoSmithKline; has received personal fees from Novartis, Boehringer Ingelheim, Merck, Astra Zeneca, Bristol-Myers Squibb, and Roche; and has advisory roles with Novartis, Bayer, and Boehringer Ingelheim. Dr. Wistuba has received grants from Genentech/Roche, Bristol-Myers Squibb, HTG Molecular, Merck, Asuragen, Pfizer, Astra Zeneca/Medimmune, Oncoplex, Amgen, Takeda, EMD Serono, Medimmune, Adaptive, DepArray, and Karus; and has received personal fees from Genentech/Roche, Bristol-Myers Squibb, Boehringer Ingelheim, Medscape, HTG Molecular, Merck, Asuragen, Pfizer, and Astra Zeneca/Medimmune. Dr. Carbone has received personal fees from Abbvie, Adaptimmune, Agenus, Amgen, Ariad, Astra Zeneca, Biocept, Boehringer Ingelheim, Celgene, EMD Serono, Inc., Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Inovio, Merck, Merck Sharp & Dohme, Novartis, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, and Takeda; and has received grants from Bristol-Myers Squibb. Dr. Hirsch is co-inventor of a University of Colorado–owned patent: "EGFR IHC and- FISH as predictive biomarkers for EGFR Therapy"; and is on advisory boards for Abbvie, Astra Zeneca, Biocept, Bristol-Myers Squibb, HTG, Lilly, Merck, Novartis, Pfizer, Roche/Genentech, and Ventana. Dr. Wistuba has received grants and personal fees from Genentech/Roche, Bristol-Myers Squibb, Genentech/Roche, HTG Molecular, Lilly, Merck, Pfizer, and Ventana; and has received laboratory research grants (through the University of Colorado) from Genentech, Bristol-Myers Squibb, Lilly, Bayer, and Clovis Oncology. Dr. Gandara has received personal fees from Foundation Medicine and Guardant Health. The remaining authors declare no conflict of interest.